Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;94(2):141-155.
doi: 10.1007/s00280-024-04694-0. Epub 2024 Jul 13.

Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients

Siti Utami Rahmayanti #  1 , Riezki Amalia #  2 , Taofik Rusdiana #  3
Affiliations

Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients

Siti Utami Rahmayanti et al. Cancer Chemother Pharmacol. 2024 Aug.

Abstract

Variations in pharmacokinetic responses to high-dose methotrexate are essential for the prognosis and management of toxicity in the treatment of pediatric acute lymphoblastic leukemia (ALL) patients. This systematic review aimed to identify and evaluate genetic polymorphisms that are significantly associated with the pharmacokinetic parameters of methotrexate during the consolidation phase of pediatric ALL treatment. Using the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines, we systematically reviewed the literature from 2013 to 2023. The databases used were PubMed and Scopus. The outcomes of interest are the study design, patient characteristics, sample size, chemotherapy protocol utilized, pharmacokinetic parameters identified, and genetic polymorphisms implicated. We included 31 articles in the qualitative synthesis and found that the SLCO1B1, ABCB1, ABCC2, and MTHFR genes appear to play significant roles in MTX metabolism and clearance. Among these, variations in SLCO1B1 have the most significant and consistent impact on methotrexate clearance. These implicated variants may contribute to the precision and tailoring of HD-MTX treatment in pediatric ALL patients.

Keywords: Genetic polymorphisms; High-dose methotrexate; Pediatric acute lymphoblastic leukemia; Personalized medicine; Pharmacokinetics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. SEER (2023) Cancer Stat Facts: Childhood Leukemia (Ages 0–19). In: The Surveillance Research Program (SRP) in NCI’s Division of Cancer Control and Population Sciences (DCCPS) [Accessed Januari 2024]
    1. Brown P, Inaba H, Annesley C et al (2020) Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 18:81–112 - PubMed - DOI
    1. Inaba H, Mullighan CG (2020) Pediatric acute lymphoblastic leukemia. Hematologica 105:2524–2539 - DOI
    1. Daetwyler E, Bargetzi M, Otth M, Scheinemann K (2022) Late effects of high-dose methotrexate treatment in childhood cancer survivors—a systematic review. BMC Cancer 22:267 - PubMed - PMC - DOI
    1. Xu M, Wu S, Wang Y, Zhao Y, Wang X, Wei C, Liu X, Hao F, Hu C (2022) Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia. Front Pharmacol. https://doi.org/10.3389/fphar.2022.1003812 - DOI - PubMed - PMC

Publication types

MeSH terms

Substances

LinkOut - more resources